Detailed analysis of the “Fibrosis-Pipeline Review, H1 2017” helps to understand the various types of Continuous Positive Airway Pressure (CPAP) Machine products that are currently in use, along with the variants that would gain prominence in the future.
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Fibrosis – Pipeline Review, H1 2017, provides an overview of the Fibrosis (Musculoskeletal Disorders) pipeline landscape.
Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the muscle has been damaged to fill in the open spaces in the injured muscle, providing more surface area for the regenerating muscle fibers to adhere to. The connective tissue cells that comprise scar tissue are unable to contract and relax to enable movement. The abnormal development of fibrosis causes muscle weakness, fatigue, and an inability to perform activities. Treatment includes anti-fibrosis agents and surgery.
Key Companies Mentioned:
Acceleron Pharma Inc, Aelis Farma SAS, Allakos Inc, Anima Biotech Ltd, Bristol-Myers Squibb Company, Calypso Biotech SA, Complexa Inc, Encycle Therapeutics Inc, F. Hoffmann-La Roche Ltd, Five Prime Therapeutics Inc, Genfit SA, GlycoMimetics Inc, Hanmi Pharmaceuticals Co Ltd, iBio Inc, Immunomet Therapeutics Inc, Inception Sciences Inc, Insmed Inc, Inventiva, Ironwood Pharmaceuticals Inc, Isarna Therapeutics GmbH, Lycera Corp, Neumedicines Inc,Novartis AG, Palatin Technologies Inc, Ribomic Inc, Scholar Rock Inc, SciFluor Life Sciences LLC, SK Chemicals Co Ltd, UCB SA and VivaCell Biotechnology Espana SL
Place a direct purchase order on this report at http://www.orbisresearch.com/contact/purchase/246985 . AND if you have enquire before buying this report visit at http://www.orbisresearch.com/contacts/enquiry-before-buying/246985 .
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Fibrosis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Browse this full report @ http://www.orbisresearch.com/reports/index/fibrosis-pipeline-review-h1-2017 .
The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 30 and 17 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Fibrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Request a sample for this report @ http://www.orbisresearch.com/contacts/request-sample/246985 .
– The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosis (Musculoskeletal Disorders).
– The pipeline guide reviews pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Fibrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Fibrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosis (Musculoskeletal Disorders)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Fibrosis (Musculoskeletal Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Fibrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
List of Figures
Number of Products under Development for Fibrosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: firstname.lastname@example.org
Follow Us on Linkedin: https://www.linkedin.com/company/orbis-research